Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Immuneering Corp Cl A (IMRX)

Immuneering Corp Cl A (IMRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 143,379
  • Shares Outstanding, K 26,405
  • Annual Sales, $ 2,080 K
  • Annual Income, $ -33,540 K
  • 60-Month Beta -2.23
  • Price/Sales 71.09
  • Price/Cash Flow N/A
  • Price/Book 1.21
Trade IMRX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.58
  • Number of Estimates 5
  • High Estimate -0.54
  • Low Estimate -0.61
  • Prior Year -0.42
  • Growth Rate Est. (year over year) -38.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.00 +3.60%
on 12/09/22
9.87 -47.52%
on 11/10/22
-3.47 (-40.12%)
since 11/09/22
3-Month
5.00 +3.60%
on 12/09/22
16.17 -67.96%
on 09/30/22
-3.69 (-41.60%)
since 09/09/22
52-Week
3.74 +38.50%
on 05/25/22
23.67 -78.12%
on 12/22/21
-16.69 (-76.31%)
since 12/09/21

Most Recent Stories

More News
Immuneering Corporation (IMRX) Reports Q3 Loss, Lags Revenue Estimates

Immuneering Corporation (IMRX) delivered earnings and revenue surprises of -2.08% and 92.17%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

IMRX : 5.18 (-4.60%)
TWST : 24.42 (-7.25%)
What Makes Immuneering Corporation (IMRX) a New Buy Stock

Immuneering Corporation (IMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

IMRX : 5.18 (-4.60%)
Wall Street Analysts See a 148% Upside in Immuneering Corporation (IMRX): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 148% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable,...

IMRX : 5.18 (-4.60%)
Pyramid Biosciences Names Biren Amin as Chief Financial and Strategy Officer

Pyramid Biosciences, Inc., a Boston-based, clinical-stage, biotechnology company focused on developing new and highly differentiated precision therapies for cancer, today announced the expansion of its...

IMRX : 5.18 (-4.60%)
Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104

Immuneering (IMRX) files an investigational new drug (IND) application to the FDA to start a phase I/IIa study on IMM-1-104 for the treatment of advanced RAS mutant solid tumors. Stock up.

ATRA : 4.45 (-6.12%)
ORIC : 3.18 (-1.70%)
ACHL : 1.3000 (+2.36%)
IMRX : 5.18 (-4.60%)
Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 224%: Here's is How to Trade

The consensus price target hints at a 223.5% upside potential for Immuneering Corporation (IMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

IMRX : 5.18 (-4.60%)
Immuneering Corporation (IMRX) Reports Q2 Loss, Misses Revenue Estimates

Immuneering Corporation (IMRX) delivered earnings and revenue surprises of 15.38% and 65.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

IMRX : 5.18 (-4.60%)
FULC : 5.45 (-11.24%)
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Lags Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -14.71% and 9.37%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

KYMR : 25.90 (-1.15%)
IMRX : 5.18 (-4.60%)
Lumos (LUMO) Soars 9.4%: Is Further Upside Left in the Stock?

Lumos (LUMO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

LUMO : 3.62 (-13.81%)
IMRX : 5.18 (-4.60%)
Immuneering Announces Participation in William Blair Biotech Focus Conference 2022

CAMBRIDGE, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational...

IMRX : 5.18 (-4.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Immuneering Corporation is a biopharmaceutical company advancing a pipeline of oncology and neuroscience product candidates. The company's product candidate includes IMM-1-104. Immuneering Corporation is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 6.14
2nd Resistance Point 5.87
1st Resistance Point 5.53
Last Price 5.18
1st Support Level 4.92
2nd Support Level 4.65
3rd Support Level 4.31

See More

52-Week High 23.67
Fibonacci 61.8% 16.06
Fibonacci 50% 13.70
Fibonacci 38.2% 11.35
Last Price 5.18
52-Week Low 3.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar